45 results about "Osteocalcin" patented technology

The invention relates to a method of identifying a compound that affects osteocalcin activity, comprising obtaining a 3D structure of osteocalcin or a fragment thereof, designing a compound to interact with, or mimic, the 3D structure of osteocalcin or fragment thereof, obtaining the compound, and determining whether the compound affects osteocalcin activity.

An application of fully carboxylated osteocalcin in preparing a fast-acting antidepressant. The fully carboxylated osteocalcin is administered at a concentration of 80 ng / g.

The invention discloses the use of osteocalcin to prepare Parkinson's disease treatment drug; the invention finds that exogenous administration of osteocalcin can improve the motor dysfunction of the Parkinson's disease rat model and alleviate its nigrostriatum Loss of dopaminergic neurons can alleviate PC12 cell apoptosis caused by 6‑OHDA through the AKT / GSK pathway in vitro. Therefore, osteocalcin, as a small molecule polypeptide hormone that can pass through the blood-brain barrier, can become a new drug for preventing and treating Parkinson's disease.

The invention belongs to the field of medicine in-vitro diagnosis, and particularly relates to a calibration product of an osteocalcin detection reagent and a preparation method thereof. Due to addingof a composite protection substance composed of an excipient, a surfactant, a stabilizer and a preservative, the calibration product is high in stability and can be stable for one month at room temperature, can be stable at 20 DEG C for one year; the preparation method can trace to international or national reference substance, so that accuracy of clinical result. The calibration product is suitable for industrial large-scale production, the problem that existing calibration products are unstable in preservation is solved, and production cost is lowered.

The invention encompasses compositions and methods for effectively treating and / or preventing the development and / or progression of osteoporosis and related disorders such as osteoarthritis and rheumatoid arthritis, and for promoting overall bone and joint health. This is accomplished by addressing multiple key mechanisms that lead to such disorders. The invention includes compositions comprising a combination of agents having biological activities that effectively suppress, regulate or interfere with the various key biochemical processes and mechanisms that increase the risk for development and / or progression of osteoporosis. The present compositions and methods simultaneously promote bone formation and reduce bone resorption by (a) stimulating osteoblast formation and osteogenesis; (b) suppressing adipocyte differentiation; (c) inhibiting osteoclast formation; and (d) increasing apoptosis of osteoclasts. The inventive compositions used for administration to human and other mammalian subjects having or at risk for development of osteoporosis comprise (1) at least one agent capable of modulating expression and / or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT / enhancer binding protein-α (C / EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent that activates expression and / or activity of one or more of the osteogenic transcription factors (Runx2 / Cbfα1, Dlx5, Osterix, Msx2); (3) at least one agent that activates expression and / or activity of one or more of bone morphogenetic proteins (BMPs: BMP 2 and 4), alkaline phosphatase (ALP), and osteocalcin; (4) at least one agent capable of activating Wnt / β-catenin signaling pathway; (5) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (6) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); and (7) at least one agent that induces the expression of and / or activates one or more of adenosine monophosphate-activated protein kinase (AMPK), sirtuin (SIRT1) and adiponectin (AP).